US OKs Mallinckrodt's power injection for MRI (magnetic resonance imaging) agent:
This article was originally published in Clinica
Executive Summary
Mallinckrodt claims it has become the first company to gain US approval to market a power injection delivery approach for administering an MRI contrast agent. The 1-2 mL/second rate of injection with a power injector, which was cleared for use with its OPTIMARK contrast media, positions the agent as a fast and safe solution for a variety of MRI requirements, says Mallinckrodt, a business of Tyco Healthcare.